IDYN - ETF AI Analysis
Top Page
iShares International Equity Factor Rotation Active ETF (IDYN)
Rating:65Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid gains so far this year, indicating that its strategy has recently been working well for investors.
Leading Holding with Very Strong Gains
The largest position, ASML Holding, has shown very strong performance, providing a meaningful boost to the fund’s overall returns.
Broad International Diversification
Holdings spread across many countries such as Japan, the UK, the U.S., and several European and Asia-Pacific markets help reduce reliance on any single economy.
Negative Factors
Moderate Expense Ratio
The fund’s fee is higher than many simple index ETFs, which slightly reduces the net return investors keep over time.
Recent Short-Term Weakness
The ETF has slipped over the past month, showing that returns can be bumpy even when longer-term performance looks better.
Mixed Performance Among Top Holdings
While several major positions have done well, at least one large holding like AstraZeneca has been weak, which can drag on overall results.
IDYN vs. SPDR S&P 500 ETF (SPY)
AUM108.41M
RegionGlobal Ex-U.S.
Expense Ratio0.45%
Beta0.88
IssueriShares
Inception DateAug 05, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,779
30 Day Avg. Volume14,226
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
34.64Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering186
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDYN Summary
The iShares International Equity Factor Rotation Active ETF (IDYN) is an actively managed fund that invests in large and mid-sized companies outside the U.S., aiming to beat the broader international stock market by shifting its mix of stocks as conditions change. It owns well-known global names like ASML Holding and Novartis, and spreads money across many countries such as Japan, the UK, and Germany, with some exposure to faster-growing emerging markets. Investors might consider IDYN for international diversification and long-term growth potential. However, its value can go up and down with global stock markets, and active strategies may not always outperform.
How much will it cost me?This ETF has an expense ratio of 0.45%, which means you’ll pay about $4.50 per year for every $1,000 you invest. That’s higher than the cost of many simple index ETFs because this fund is actively managed and uses a factor-rotation strategy that requires more research and trading.
What would affect this ETF?This ETF could benefit if international economic growth improves, especially in Europe and other markets outside the U.S., boosting industrial, financial, and healthcare companies like ASML, Novartis, and AstraZeneca, and if global stock markets reward the fund’s flexible, factor-based strategy. On the other hand, it could be hurt by slower growth or financial stress in non-U.S. economies, rising interest rates that pressure banks and utilities, energy or regulatory shocks affecting companies like Enel and Siemens Energy, or if its active rotation strategy picks factors that fall out of favor.
IDYN Top 10 Holdings
IDYN leans heavily on international financials and health care, with names like Mitsubishi UFJ and Banco Santander quietly powering the fund thanks to their rising share prices and solid fundamentals. Novartis has been a steady engine in the health care sleeve, while Iberdrola and Enel add a more defensive, utility-like flavor with generally positive, if measured, momentum. On the flip side, ASML’s mixed, recently lagging performance and AstraZeneca’s losing steam have been modest drags. Overall, it’s a diversified ex-U.S. mix, but with a noticeable tilt toward European banks and pharma.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 3.92% | $4.20M | €550.06B | 141.04% | 76 Outperform | |
| Novartis AG | 3.03% | $3.25M | CHF232.08B | 34.41% | 80 Outperform | |
| AstraZeneca | 2.38% | $2.56M | $265.97B | 13.76% | 80 Outperform | |
| Iberdrola | 1.89% | $2.03M | €135.32B | 35.28% | 67 Neutral | |
| Banco Santander | 1.84% | $1.97M | €179.72B | 66.93% | 73 Outperform | |
| ― | 1.70% | $1.82M | ― | ― | ― | |
| Enel S.p.A. | 1.63% | $1.75M | €99.96B | 28.80% | 67 Neutral | |
| Assicurazioni Generali S.p.A. | 1.57% | $1.69M | €67.23B | 37.77% | 63 Neutral | |
| Mitsubishi UFJ Financial Group | 1.57% | $1.69M | ¥39.42T | 51.41% | 76 Outperform | |
| Vodafone | 1.45% | $1.55M | £27.51B | 42.23% | 63 Neutral |
IDYN Technical Analysis
Positive
―
Price Trends
30.01
Positive
29.70
Positive
28.96
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDYN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.93, equal to the 50-day MA of 30.01, and equal to the 200-day MA of 28.96, indicating a bullish trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYN.
IDYN Peer Comparison
Comparison Results
Performance Comparison
IDYN
iShares International Equity Factor Rotation Active ETF
30.22
5.05
20.06%
JDVI
John Hancock Disciplined Value International Select ETF
―
―
―
OSEA
Harbor International Compounders ETF
―
―
―
BRIE
MFS Blended Research International Equity ETF
―
―
―
QLTI
GMO International Quality ETF
―
―
―
BAIV
Brown Advisory International Value Select ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents